In a groundbreaking advancement poised to shift paradigms in infectious disease research, a recent comprehensive study has illuminated the intricate genetic underpinnings of antimicrobial tolerance in Mycobacterium abscessus. Traditionally, drug tolerance—where bacterial populations survive lethal drug concentrations without acquiring full resistance—has been considered a primarily phenotypic and transient state. However, this new research plunges deeper, revealing that drug tolerance is far from merely a reversible phenotypic adaptation. Instead, it is substantially driven by genetic factors encoded within the bacterial genome.
Researchers employed cutting-edge whole-genome sequencing to explore the relationship between bacterial genetic variation and antimicrobial tolerance. By analyzing an extensive dataset of 1.3 million M. abscessus unitigs, which are sequence fragments capturing diverse genomic variations, the team mapped these to phenotypic profiles of drug resistance and tolerance. Using linear mixed models, which account for complex genetic relationships and environmental factors, they could carefully dissect the fraction of phenotypic variance attributable to genetic variance—a measure known as heritability.
The most striking revelation from their analysis was the high heritability of tolerance phenotypes across various antibiotics. Contrary to prior assumptions of tolerance being primarily a plastic, non-genetic feature, the data indicate that for many drugs, genetic determinants account for between 32% and an astonishing 97% of the variability in tolerance levels between isolates. This far exceeds the minimal 1.1% heritability expected by chance, underscoring the heritable and strain-specific nature of drug killing phenotypes.
The team further contrasted heritability estimates between drug resistance, measured as minimum inhibitory concentrations (MICs), and tolerance, assessed via the area under the killing curve (AUC), highlighting that while resistance to some antibiotics such as macrolides was strongly genetically determined, others like imipenem and cefoxitin showed low heritability. This likely reflects the interplay of drug chemical properties and biological variability affecting phenotypic measurements, providing critical insights into heterogeneity in resistance and tolerance mechanisms.
Beyond quantifying heritability, the researchers integrated these data with detailed phylogenetic analyses of over 350 M. abscessus isolates. This evolutionary perspective enabled them to characterize how tolerance traits have emerged and been conserved across bacterial lineages. Strikingly, both convergent evolution and clade-specific inheritance patterns were evident. For example, distinct high- or low-tolerance phenotypes have evolved independently multiple times—a phenomenon known as homoplasy—while other traits are inherited within closely related clades.
One particularly noteworthy finding was the identification of a low tigecycline tolerance clade nested within the dominant circulating clone of M. abscessus massiliense. This clade also harbors high-level mutational resistance to aminoglycosides and macrolides and is associated with increased virulence, highlighting a paradox where high genetic drug resistance coincides with vulnerabilities in drug tolerance. The low tolerance to tigecycline within this clade could represent an exploitable therapeutic weakness, offering new avenues to improve treatment outcomes for infections notoriously difficult to manage.
The implications of this study extend far beyond mere academic interest. Understanding that tolerance, like resistance, has a strong genetic basis challenges established dogma and opens new research pathways. Therapeutic strategies could be refined considering not only resistance profiles but also tolerance genotypes, enabling more precise combination therapies that prevent both survival and proliferation of pathogenic strains.
Equally remarkable is the study’s demonstration that large-scale phenotypic screens coupled with whole genome sequencing and sophisticated statistical modeling provide a powerful lens to map the complex genotype-phenotype landscape in microorganisms. This approach serves as a blueprint for dissecting genetic contributions to other complex traits in diverse infectious agents, potentially revolutionizing antimicrobial stewardship and drug development.
Moreover, the heterogeneity observed in both resistance and tolerance suggests that treatment failures and relapses in mycobacterial infections may stem as much from genetically encoded tolerance as from resistance mutations. Clinical microbiology diagnostics may need to incorporate tolerance assessments, enhancing predictive precision for therapeutic success and reducing the mounting burden of chronic infections.
This research also spotlights the nuanced relationships between genetic variation, bacterial physiology, and antimicrobial lethality, emphasizing that phenotypic assays alone cannot capture the full biology of tolerance. Comprehensively integrating high-resolution genotype data enables identification of subtle genetic variants controlling tolerance across populations, which could be missed by conventional methods.
By mapping killing phenotypes onto the bacterial phylogeny, the study reveals how evolutionary pressures shape drug response strategies in bacterial populations. These dynamics of clonal inheritance and repeated emergence of similar traits underscore evolutionary constraints and plasticity in antimicrobial survival mechanisms, encouraging deeper evolutionary-informed drug design.
Ultimately, this work represents a paradigm shift with wide-reaching consequences for clinicians, microbiologists, and pharmacologists. The discovery that drug tolerance is not simply a transient phenotypic state but is robustly genetically encoded gives actionable insight into combatting mycobacterial infections with higher lethality rates and poorer clinical outcomes. A refined understanding of the genetic landscape controlling tolerance holds promise for enhanced diagnostics, targeted therapeutics, and improved patient prognoses worldwide.
As multidrug-resistant infections continue to jeopardize global health, deciphering the genetic architecture of tolerance in pathogens like M. abscessus emerges as an urgent priority. This seminal study lays vital groundwork for future investigations and therapeutic innovations that can transform our ability to outmaneuver antimicrobials evasion.
Subject of Research: Genetic determinants of antimicrobial tolerance and resistance in Mycobacterium abscessus.
Article Title: Large-scale testing of antimicrobial lethality at single-cell resolution predicts mycobacterial infection outcomes.
Article References:
Jovanovic, A., Bright, F.K., Sadeghi, A. et al. Large-scale testing of antimicrobial lethality at single-cell resolution predicts mycobacterial infection outcomes. Nat Microbiol (2026). https://doi.org/10.1038/s41564-025-02217-y
Image Credits: AI Generated
